The Experts below are selected from a list of 201 Experts worldwide ranked by ideXlab platform
Yutaka Nakaya - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Newcastle Disease Virus as a Vaccine Vector Recombinant Newcastle Disease Virus as a Vaccine Vector
Journal of Virology, 2001Co-Authors: Takaaki Nakaya, A Sagrera, Adolfo Garci, Jerome Cros, M S Park, Enrique Villar, Peter Palese, H. Zheng, Yutaka NakayaAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector.
Enrique Villar - One of the best experts on this subject based on the ideXlab platform.
-
Gangliosides and N-glycoproteins function as Newcastle Disease Virus receptors
The International Journal of Biochemistry & Cell Biology, 2004Co-Authors: Laura Ferreira, Enrique Villar, Isabel Muñoz-barrosoAbstract:Abstract The interaction of enveloped Viruses with cell surface receptors is the first step in the viral cycle and an important determinant of viral host range. Although it is established that the paramyxoVirus Newcastle Disease Virus binds to sialic acid-containing glycoconjugates the exact nature of the receptors has not yet been determined. Accordingly, here we attempted to characterize the cellular receptors for Newcastle Disease Virus. Treatment of cells with tunicamycin, an inhibitor of protein N-glycosylation, blocked fusion and infectivity, while the inhibitor of O-glycosylation benzyl-N-acetyl-α- d -galactosamide had no effect. Additionally, the inhibitor of glycolipid biosynthesis 1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol blocked viral fusion and infectivity. These results suggest that N-linked glycoproteins and glycolipids would be involved in viral entry but not O-linked glycoproteins. The ganglioside content of COS-7 cells was analyzed showing that GD1a was the major ganglioside component; the presence of GM1, GM2 and GM3 was also established. In a thin-layer chromatographic binding assay, we analyzed the binding of the Virus to different gangliosides, detecting the interaction with monosialogangliosides such as GM3, GM2 and GM1; disialogangliosides such as GD1a and GD1b, and trisialogangliosides such as GT1b. Unlike with other Viruses, our results seem to point to the absence of a specific pattern of gangliosides that interact with Newcastle Disease Virus. In conclusion, our results suggest that Newcastle Disease Virus requires different sialic acid-containing compounds, gangliosides and glycoproteins for entry into the target cell. We propose that gangliosides would act as primary receptors while N-linked glycoproteins would function as the second receptor critical for viral entry.
-
Recombinant Newcastle Disease Virus as a vaccine vector
J.Virol., 2001Co-Authors: Takaichi Nakaya, Yuuta Nakaya, A Sagrera, Jerome Cros, M S Park, Enrique Villar, Adolfo García-sastre, H. Zheng, Peter PaleseAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector
-
Recombinant Newcastle Disease Virus as a Vaccine Vector Recombinant Newcastle Disease Virus as a Vaccine Vector
Journal of Virology, 2001Co-Authors: Takaaki Nakaya, A Sagrera, Adolfo Garci, Jerome Cros, M S Park, Enrique Villar, Peter Palese, H. Zheng, Yutaka NakayaAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector.
Peter Palese - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Newcastle Disease Virus as a vaccine vector
J.Virol., 2001Co-Authors: Takaichi Nakaya, Yuuta Nakaya, A Sagrera, Jerome Cros, M S Park, Enrique Villar, Adolfo García-sastre, H. Zheng, Peter PaleseAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector
-
Recombinant Newcastle Disease Virus as a Vaccine Vector Recombinant Newcastle Disease Virus as a Vaccine Vector
Journal of Virology, 2001Co-Authors: Takaaki Nakaya, A Sagrera, Adolfo Garci, Jerome Cros, M S Park, Enrique Villar, Peter Palese, H. Zheng, Yutaka NakayaAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector.
Takaaki Nakaya - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Newcastle Disease Virus as a Vaccine Vector Recombinant Newcastle Disease Virus as a Vaccine Vector
Journal of Virology, 2001Co-Authors: Takaaki Nakaya, A Sagrera, Adolfo Garci, Jerome Cros, M S Park, Enrique Villar, Peter Palese, H. Zheng, Yutaka NakayaAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector.
M S Park - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Newcastle Disease Virus as a vaccine vector
J.Virol., 2001Co-Authors: Takaichi Nakaya, Yuuta Nakaya, A Sagrera, Jerome Cros, M S Park, Enrique Villar, Adolfo García-sastre, H. Zheng, Peter PaleseAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector
-
Recombinant Newcastle Disease Virus as a Vaccine Vector Recombinant Newcastle Disease Virus as a Vaccine Vector
Journal of Virology, 2001Co-Authors: Takaaki Nakaya, A Sagrera, Adolfo Garci, Jerome Cros, M S Park, Enrique Villar, Peter Palese, H. Zheng, Yutaka NakayaAbstract:A complete cDNA clone of the Newcastle Disease Virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant Virus expressing an influenza Virus hemagglutinin was generated by reverse genetics. The rescued Virus induces a strong humoral antibody response against influenza Virus and provides complete protection against a lethal dose of influenza Virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector.